How much revenue did Mithra Pharmaceuticals generate this year?
Mithra Pharmaceuticals has achieved a revenue of 66.13 M EUR this year.
Mithra Pharmaceuticals Revenue 2024
Mithra Pharmaceuticals Revenue
66.13 M EUR
Ticker
MITRA.BR
ISIN
BE0974283153
WKN
A14V4E
In 2024, Mithra Pharmaceuticals's sales reached 66.13 M EUR, a 64.68% difference from the 40.16 M EUR sales recorded in the previous year.
The Mithra Pharmaceuticals Revenue history
| YEAR | REVENUE (undefined EUR) | GROSS MARGIN (%) |
|---|---|---|
| 2026e | 118.97 | 15,30 |
| 2025e | 84.77 | 21,48 |
| 2024e | 66.13 | 27,53 |
| 2023 | 40.16 | 45,34 |
| 2022 | 67 | 70,71 |
| 2021 | 22.67 | 30,63 |
| 2020 | 9.03 | 61,72 |
| 2019 | 96.52 | 97,42 |
| 2018 | 57.88 | 97,29 |
| 2017 | 32.04 | 91,90 |
| 2016 | 22.47 | 59,81 |
| 2015 | 20.44 | 50,11 |
| 2014 | 19.04 | 31,63 |
Mithra Pharmaceuticals Revenue, EBIT, Net Income BE0974283153 · A14V4E
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Mithra Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Mithra Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Mithra Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Mithra Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Mithra Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Mithra Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Mithra Pharmaceuticals’s growth potential.
Mithra Pharmaceuticals Revenue, EBIT and net profit per share
| Date | Mithra Pharmaceuticals Revenue | Mithra Pharmaceuticals EBIT | Mithra Pharmaceuticals Net Income |
|---|---|---|---|
| 2026e | 118.97 M undefined | 50.37 M undefined | 44.11 M undefined |
| 2025e | 84.77 M undefined | 19.36 M undefined | 13.78 M undefined |
| 2024e | 66.13 M undefined | -24.36 M undefined | -23.02 M undefined |
| 2023 | 40.16 M undefined | -64.99 M undefined | -173.5 M undefined |
| 2022 | 67 M undefined | -26.25 M undefined | -59.62 M undefined |
| 2021 | 22.67 M undefined | -87.88 M undefined | -116.88 M undefined |
| 2020 | 9.03 M undefined | -83.68 M undefined | -92.09 M undefined |
| 2019 | 96.52 M undefined | 26.98 M undefined | -26.56 M undefined |
| 2018 | 57.88 M undefined | 14.19 M undefined | -12.36 M undefined |
| 2017 | 32.04 M undefined | -26.16 M undefined | -35.01 M undefined |
| 2016 | 22.47 M undefined | -35.98 M undefined | -35.09 M undefined |
| 2015 | 20.44 M undefined | -14.27 M undefined | -9.82 M undefined |
| 2014 | 19.04 M undefined | -2.93 M undefined | -2.96 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2014 | 19.04 M EUR | -2.93 M EUR | -2.96 M EUR |
| 2015 | 20.44 M EUR | -14.27 M EUR | -9.82 M EUR |
| 2016 | 22.47 M EUR | -35.98 M EUR | -35.09 M EUR |
| 2017 | 32.04 M EUR | -26.16 M EUR | -35.01 M EUR |
| 2018 | 57.88 M EUR | 14.19 M EUR | -12.36 M EUR |
| 2019 | 96.52 M EUR | 26.98 M EUR | -26.56 M EUR |
| 2020 | 9.03 M EUR | -83.68 M EUR | -92.09 M EUR |
| 2021 | 22.67 M EUR | -87.88 M EUR | -116.88 M EUR |
| 2022 | 67 M EUR | -26.25 M EUR | -59.62 M EUR |
| 2023 | 40.16 M EUR | -64.99 M EUR | -173.5 M EUR |
| 2024e | 66.13 M EUR | -24.36 M EUR | -23.02 M EUR |
| 2025e | 84.77 M EUR | 19.36 M EUR | 13.78 M EUR |
| 2026e | 118.97 M EUR | 50.37 M EUR | 44.11 M EUR |
Mithra Pharmaceuticals stock margins BE0974283153 · A14V4E
The Mithra Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Mithra Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Mithra Pharmaceuticals.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Mithra Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Mithra Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Mithra Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Mithra Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Mithra Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Mithra Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Mithra Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Mithra Pharmaceuticals Margin History
| Mithra Pharmaceuticals Gross margin | Mithra Pharmaceuticals Profit margin | Mithra Pharmaceuticals EBIT margin | Mithra Pharmaceuticals Profit margin |
|---|---|---|---|
| 2026e | 45.34 % | 42.34 % | 37.07 % |
| 2025e | 45.34 % | 22.84 % | 16.26 % |
| 2024e | 45.34 % | -36.84 % | -34.81 % |
| 2023 | 45.34 % | -161.84 % | -432.08 % |
| 2022 | 70.71 % | -39.17 % | -88.99 % |
| 2021 | 30.63 % | -387.66 % | -515.59 % |
| 2020 | 61.72 % | -926.67 % | -1,019.78 % |
| 2019 | 97.42 % | 27.95 % | -27.52 % |
| 2018 | 97.29 % | 24.51 % | -21.36 % |
| 2017 | 91.9 % | -81.65 % | -109.25 % |
| 2016 | 59.81 % | -160.12 % | -156.16 % |
| 2015 | 50.11 % | -69.82 % | -48.06 % |
| 2014 | 31.63 % | -15.38 % | -15.52 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2014 | 31.63 % | -15.38 % | -15.52 % |
| 2015 | 50.11 % | -69.82 % | -48.06 % |
| 2016 | 59.81 % | -160.12 % | -156.16 % |
| 2017 | 91.9 % | -81.65 % | -109.25 % |
| 2018 | 97.29 % | 24.51 % | -21.36 % |
| 2019 | 97.42 % | 27.95 % | -27.52 % |
| 2020 | 61.72 % | -926.67 % | -1,019.78 % |
| 2021 | 30.63 % | -387.66 % | -515.59 % |
| 2022 | 70.71 % | -39.17 % | -88.99 % |
| 2023 | 45.34 % | -161.84 % | -432.08 % |
| 2024e | 45.34 % | -36.84 % | -34.81 % |
| 2025e | 45.34 % | 22.84 % | 16.26 % |
| 2026e | 45.34 % | 42.34 % | 37.07 % |
Mithra Pharmaceuticals Aktienanalyse
What does Mithra Pharmaceuticals do?
Mithra Pharmaceuticals SA is a Belgian pharmaceutical company specializing in women's health and hormone therapy. The company was founded in 1999 by François Fornieri and Jean-Michel Foidart and has since become a major player in women's healthcare. Its unique business model covers the entire value chain of the pharmaceutical industry, including research and development, production, distribution, and marketing of its own products. Mithra Pharmaceuticals SA collaborates with other pharmaceutical companies, universities, and public research institutions worldwide, aiming to offer innovative products and services based on new technologies and scientific knowledge. The company's divisions include hormone therapy, contraception, gynecology, and dermatology, providing a wide range of products and services tailored to women's needs. One of its notable products is the Estetrol patch, a safe and effective contraceptive containing a natural estrogen hormone produced during pregnancy. In gynecology, Mithra Pharmaceuticals SA offers products for the treatment of menstrual disorders, endometriosis, and vaginal dryness, such as the Estelle pill concept, which combines contraception and hormone regulation. In dermatology, the company provides skincare products based on natural ingredients, specifically designed for women with sensitive skin or skin issues. Overall, Mithra Pharmaceuticals SA focuses on meeting the needs of women and has a history of adapting to market conditions and offering innovative products and services. With its global presence and innovative products, Mithra Pharmaceuticals SA is well-positioned for future success. Mithra Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Mithra Pharmaceuticals's Sales Figures
The sales figures of Mithra Pharmaceuticals originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Mithra Pharmaceuticals’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Mithra Pharmaceuticals's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Mithra Pharmaceuticals’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Mithra Pharmaceuticals stock
How much was the turnover of the company Mithra Pharmaceuticals compared to the previous year?
The revenue of Mithra Pharmaceuticals has increased by 64.68% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Mithra Pharmaceuticals?
The revenue of Mithra Pharmaceuticals is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Mithra Pharmaceuticals measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Mithra Pharmaceuticals so important for investors?
The revenue of Mithra Pharmaceuticals is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Mithra Pharmaceuticals pay?
Over the past 12 months, Mithra Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mithra Pharmaceuticals is expected to pay a dividend of 0 EUR.
What is the dividend yield of Mithra Pharmaceuticals?
The current dividend yield of Mithra Pharmaceuticals is .
When does Mithra Pharmaceuticals pay dividends?
Mithra Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Mithra Pharmaceuticals?
Mithra Pharmaceuticals paid dividends every year for the past 0 years.
What is the dividend of Mithra Pharmaceuticals?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Mithra Pharmaceuticals located?
Mithra Pharmaceuticals is assigned to the 'Health' sector.
Wann musste ich die Aktien von Mithra Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Mithra Pharmaceuticals from 9/6/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 9/6/2024.
When did Mithra Pharmaceuticals pay the last dividend?
The last dividend was paid out on 9/6/2024.
What was the dividend of Mithra Pharmaceuticals in the year 2023?
In the year 2023, Mithra Pharmaceuticals distributed 0 EUR as dividends.
In which currency does Mithra Pharmaceuticals pay out the dividend?
The dividends of Mithra Pharmaceuticals are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Mithra Pharmaceuticals
Our stock analysis for Mithra Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mithra Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Mithra Pharmaceuticals Revenue
- Mithra Pharmaceuticals Net Income
- Mithra Pharmaceuticals P/E
- Mithra Pharmaceuticals P/S
- Mithra Pharmaceuticals EBIT
- Mithra Pharmaceuticals Dividend
- Mithra Pharmaceuticals Stocks
- Mithra Pharmaceuticals Market capitalization
- Mithra Pharmaceuticals Debt
- Mithra Pharmaceuticals Liabilities
- Mithra Pharmaceuticals Equity
- Mithra Pharmaceuticals AAQS
- Mithra Pharmaceuticals Employees
- Mithra Pharmaceuticals ROE
- Mithra Pharmaceuticals ROA
- Mithra Pharmaceuticals ROCE
